Microalbuminuria, systemic inflammation, and multiorgan dysfunction in decompensated cirrhosis: evidence for a nonfunctional mechanism of hepatorenal syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

1. How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatology international · 2023
   Review
2. Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs.Theranostics · 2021
   Article
3. Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice.Hepatology (Baltimore, Md.) · 2018
   Article
4. Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome.Oncotarget · 2017
   Article
5. Diagnosis and Management of Cirrhotic Cardiomyopathy.Journal of clinical and experimental hepatology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as